BNTX:NSD-BioNTech SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 333.48

Change

-19.51 (-5.53)%

Market Cap

USD 82.28B

Volume

2.60M

Avg Analyst Target

USD 274.94 (-17.56%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

USD183.50B 53.71 41.56
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

USD22.22B N/A N/A
TECH Bio-Techne Corporation

+1.98 (+0.37%)

USD21.07B 154.73 83.80

ETFs Containing BNTX

Symbol Name Weight Mer Price(Change) Market Cap
BBP ETFis Series Trust I - Vi.. 0.00 % 0.79 %

-0.99 (-1.86%)

USD0.03B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

-2.04 (-1.17%)

USD1.96B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

-3.43 (-1.97%)

USD10.94B
FPXI First Trust International.. 0.00 % 0.70 %

-0.75 (-1.10%)

USD1.26B
FPXE First Trust IPOX Europe E.. 0.00 % 0.70 %

-0.43 (-1.30%)

USD6.00M
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-1.71 (-3.10%)

USD0.33B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.10 %

-1.03 (-1.54%)

USD0.09B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.07 (-0.88%)

USD0.52B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

+0.03 (+0.50%)

USD0.52B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.07 (-0.85%)

USD0.04B
ITEK:LSE HAN-GINS Tech Megatrend E.. 0.00 % 0.59 %

-0.21 (-1.30%)

USD0.12B
GERM ETF Managers Trust - ETFM.. 0.00 % 0.68 %

-1.03 (-2.32%)

N/A
ITEP:LSE HAN-GINS Tech Megatrend E.. 0.00 % 0.75 %

-9.90 (-0.83%)

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-4.40 (-0.28%)

N/A
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

-0.56 (-2.06%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 309.08% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 309.08% 97% A+ 98% A+
Trailing 12 Months  
Capital Gain 400.04% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 400.04% 96% A 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 143.08% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.08% 92% A- 95% A
Risk Return Profile  
Volatility (Standard Deviation) 168.71% 14% F 9% F
Risk Adjusted Return 84.80% 96% A 89% B+
Market Capitalization 82.28B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.73 35% F 46% F
Price/Book Ratio 13.44 11% F 10% F
Price / Cash Flow Ratio -6,106.30 100% A+ 98% A+
EV/EBITDA 15.10 29% F 49% F
Management Effectiveness  
Return on Equity 133.85% 100% A+ 100% A+
Return on Invested Capital 6.58% 88% B+ 70% C-
Return on Assets 68.31% 100% A+ 100% A+
Debt to Equity Ratio 16.84% 45% F 63% D
Technical Ratios  
Short Ratio 0.34 93% A 89% B+
Short Percent 2.73% 73% C 52% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.